CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH™ Nicotine Study
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ technology to deliver nicotine as quickly as 2 minutes after oral administration. Lexaria’s technology delivered 90.2% more nicotine over the first 10 minutes of the study than the concentration-matched control formulation by the 10-minute mark. To better commercialize opportunities within the nicotine sector, the company has also completed the formation of a wholly-owned subsidiary, Lexaria Nicotine Corp. "Lexaria's DehydraTECH™…